Benzodiazepines are not part of the core federal five panel drug test. Amphetamines, cocaine, marijuana, opiates, and phencyclidine make up that base panel, and additional categories such as barbiturates and benzodiazepines are add ons that agencies and private employers choose separately, according to SAMHSA's workplace drug testing resources. That single fact explains most of the confusion employers and clinics run into with benzodiazepine screening. A BZO panel is optional, it is not standardized the way the federal panel is, and the immunoassay chemistry behind it has real, documented blind spots for some of the most commonly prescribed benzodiazepines.
What the BZO panel actually screens for
BZO is the immunoassay abbreviation for the benzodiazepine drug class as a whole, not a test for one specific compound. The cup or cartridge contains an antibody that was raised against a reference benzodiazepine metabolite, usually one that resembles oxazepam or nordiazepam in structure. When a urine sample contains enough of a chemically similar compound, the antibody binds it and produces a line, or the absence of one, depending on the test format. This is a presumptive, qualitative result. The Food and Drug Administration reviews the design, performance, and package insert claims of these immunoassay devices before they can be marketed, and it draws a clear line between screening devices and the confirmatory testing that follows a non negative screen, as described on the FDA's drugs of abuse tests page.
The practical problem is that "benzodiazepine" covers a wide chemical family, and the antibody used in most commercial BZO immunoassays was never built to recognize every member of that family equally.
Which benzodiazepines get caught, and which get missed
This is the part that trips up employers who assume a positive or negative BZO result means what it sounds like. Federal guidance is explicit that most BZO immunoassays have low sensitivity to two of the most widely prescribed benzodiazepines: clonazepam and lorazepam. A Substance Abuse and Mental Health Services Administration table on urine drug testing windows of detection states that immunoassays "may not be sensitive to therapeutic doses" of benzodiazepines generally, and specifically flags that "most immunoassays have low sensitivity to clonazepam and lorazepam," recommending that testers check with their laboratory on sensitivity and cutoffs for the specific assay in use, per the SAMHSA detection window table hosted on the National Library of Medicine's bookshelf.
The chemistry reason is metabolic. Benzodiazepines that get broken down into oxazepam like or nordiazepam like metabolites tend to trigger a strong antibody response. Diazepam is a classic example, since it metabolizes into nordiazepam, temazepam, and oxazepam, all of which the typical immunoassay antibody was designed around. Clonazepam and lorazepam metabolize differently, producing conjugated forms the standard antibody does not bind as readily, which is the documented mechanism behind their weaker immunoassay performance.
| Benzodiazepine | DEA schedule | Immunoassay screening behavior |
|---|---|---|
| Diazepam (Valium) | Schedule IV | Reliable target compound; assay antibodies are typically built around its metabolites |
| Alprazolam (Xanax) | Schedule IV | Generally detected, though sensitivity varies by manufacturer and cutoff |
| Temazepam (Restoril) | Schedule IV | Generally detected as a direct diazepam metabolite target |
| Triazolam (Halcion) | Schedule IV | Short acting; detectable only in a narrow window after use |
| Clonazepam (Klonopin) | Schedule IV | Documented low immunoassay sensitivity; can screen negative on a true positive specimen |
| Lorazepam (Ativan) | Schedule IV | Documented low immunoassay sensitivity; can screen negative on a true positive specimen |
All of these compounds are Schedule IV controlled substances under the Controlled Substances Act, a classification confirmed on the Drug Enforcement Administration's controlled substance schedules page, which lists alprazolam, clorazepate, clonazepam, diazepam, lorazepam, midazolam, temazepam, and triazolam among Schedule IV substances. Schedule IV status reflects abuse potential and accepted medical use, it says nothing about how well a given immunoassay detects the drug, which is why a clinic cannot assume screening performance is uniform across the class.
Detection windows by drug and use pattern
Detection time for any benzodiazepine depends heavily on how long acting the parent drug and its metabolites are, and on whether the person used it once or regularly. The same SAMHSA detection window table gives a working range for the class as a whole: benzodiazepines are typically detectable for one to three days after use, extending to as long as six weeks with heavy, regular use of long acting benzodiazepines such as diazepam or clonazepam, whose active metabolites accumulate and clear slowly.
| Use pattern | Typical urine detection window |
|---|---|
| Single dose, short acting benzodiazepine (e.g. triazolam) | Toward the shorter end of the one to three day range |
| Single dose, longer acting benzodiazepine (e.g. diazepam, clonazepam) | One to three days, trending longer than short acting compounds |
| Heavy, regular use of a long acting benzodiazepine | Up to six weeks after the last dose |
Individual results still vary with dose, frequency, hydration, kidney and liver function, and the specific cutoff concentration a laboratory or point of care device uses, which is why the source table advises confirming assay specific sensitivity and cutoffs with the testing laboratory rather than treating any single number as fixed.
Why so few employers run a BZO panel by default
The federal Mandatory Guidelines for Federal Workplace Drug Testing Programs, which set the SAMHSA five panel used for DOT and other federally regulated testing, do not cover non federal employers at all, according to SAMHSA's own workplace drug testing FAQ page. A private employer or clinic is free to choose any panel configuration, and many add benzodiazepines specifically because of what the five panel structurally leaves out: prescription sedatives, anxiolytics, and sleep medications with real impairment and diversion risk in safety sensitive roles. That is the logic behind broader configurations like a 12 panel drug test, which layers benzodiazepines, barbiturates, and prescription opioids on top of the base five categories for employers and clinics that want that visibility.
Prescribed medication and the MRO review
A non negative BZO screen is not a finding of misconduct on its own. Employers using a Medical Review Officer process route every non negative screen to a licensed physician trained to review the result against any legitimate prescription before it becomes a reportable positive. If the donor holds a current, valid prescription for the detected benzodiazepine and the use is consistent with that prescription, the MRO can verify the result as negative for reporting purposes rather than treating it as a policy violation. This is the same layered structure described in our medical review officer process guide, and it applies whether the underlying screen is a five panel, ten panel, or twelve panel configuration. Clinics that skip an MRO review, or that use only an in house untrained reviewer, take on real legal exposure when a legitimately prescribed medication gets treated as a violation.
Because clonazepam and lorazepam can screen negative even when a person has taken them, an MRO reviewing a BZO panel also has to account for the reverse problem: a negative screen does not rule out use of those two drugs. Employers relying on a BZO panel to catch every benzodiazepine, including ones associated with impairment complaints or diversion concerns involving clonazepam or lorazepam specifically, should discuss with their laboratory whether a lower cutoff or a confirmatory test adds meaningful coverage for their situation.
Choosing panel configuration for your setting
A few practical points employers and clinics weigh when deciding whether to add BZO screening:
- DOT regulated positions must use the federally mandated five panel and cannot substitute a broader panel for compliance purposes.
- Non DOT employers in safety sensitive industries, treatment settings, and pain management practices commonly add BZO coverage because sedative and anxiolytic misuse falls outside the base five categories entirely.
- A BZO immunoassay is a screening tool, not a confirmed identification. Any non negative result should go through laboratory confirmation and MRO review before it drives an employment or clinical decision.
- Given the documented weak spot for clonazepam and lorazepam, a negative BZO screen should not be treated as proof those two drugs were absent.
Frequently asked questions
What does BZO mean on a drug test?
BZO is the abbreviation used on immunoassay cups and cartridges for the benzodiazepine drug class. A positive or non negative BZO result means the specimen reacted with the benzodiazepine antibody, not that a specific drug was identified. Identification of the exact compound requires laboratory confirmation.
Do all benzodiazepines show up equally on a BZO screen?
No. Diazepam and its metabolites, along with temazepam, are reliably picked up because most BZO antibodies were built around those metabolite structures. Clonazepam and lorazepam are documented exceptions with low immunoassay sensitivity, meaning a true positive specimen for either drug can still screen negative.
How long do benzodiazepines stay detectable in urine?
Federal guidance puts the general range at one to three days after use, extending up to six weeks with heavy, regular use of long acting benzodiazepines such as diazepam or clonazepam. Short acting compounds clear faster than long acting ones with active metabolites.
Does DOT drug testing include benzodiazepines?
No. The federally mandated five panel used for DOT testing covers amphetamines, cocaine, marijuana, opiates, and phencyclidine. Benzodiazepines are an additional category that non federal employers can choose to add, but they are not part of the DOT regulated panel.
What happens if an employee has a valid benzodiazepine prescription?
A trained Medical Review Officer reviews every non negative screen and verifies whether the donor has a legitimate, current prescription consistent with the detected drug. Verified prescription use is reported as negative rather than as a policy violation, which is why an MRO review step matters for any BZO panel an employer runs.
Related reading
This article is general information, not legal or medical advice. Panel selection, cutoff levels, and MRO review procedures should be confirmed with a qualified laboratory, Medical Review Officer, or legal counsel before use in employment or clinical decisions.
